This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
The study was funded by Boehringer Ingelheim Pharma GmbH.
Olson AL, et al. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA. Advances in Therapy : 12 May 2020. Available from: URL: http://doi.org/10.1007/s12325-020-01380-4
About this article
Cite this article
Progressive fibrosing interstitial lung disease: high care needs, high costs. PharmacoEcon Outcomes News 855, 25 (2020). https://doi.org/10.1007/s40274-020-6890-6